Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 5, 2013, Pages 879-889

  Misawa, Kiyoshi ^a   Kanazawa, Takeharu ^b   Misawa, Yuki ^a   Imai, Atsushi ^a   Uehara, Takayuki ^c   Mochizuki, Daiki ^a   Endo, Shiori ^a   Takahashi, Goro ^a   Mineta, Hiroyuki ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

DNA methylation; Galanin; Head and neck cancer; TAC1; TACR1

Indexed keywords

TACHYKININ; TACHYKININ RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DNA METHYLATION; E CADHERIN GENE; FEMALE; FOLLOW UP; GALANIN GENE; GALR1 GENE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; P16 GENE; PRIORITY JOURNAL; PROMOTER REGION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TAC1 GENE; TACR1 GENE; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROKININ A; ODDS RATIO; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, NEUROKININ-1; RECURRENCE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876288615     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1393-5     Document Type: Article

References (36)

1. Barreto SG, Carati CJ, Schloithe AC, Toouli J, Saccone GT (2010) The combination of neurokinin-1 and galanin receptor antagonists ameliorates caerulein-induced acute pancreatitis in mice. Peptides 31(2):315-321. doi: 10.1016/j.peptides.2009.11.014
2. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784. doi: 10.1038/nrd2133
3. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, Bradford CR, Carey TE (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 32(4):417-426. doi: 10.1002/hed.21198
4. Carvalho AL, Henrique R, Jeronimo C, Nayak CS, Reddy AN, Hoque MO, Chang S, Brait M, Jiang WW, Kim MM, Claybourne Q, Goldenberg D, Khan Z, Khan T, Westra WH, Sidransky D, Koch W, Califano JA (2011) Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res 17(14):4782-4789. doi: 10.1158/1078-0432.CCR-11-0324
5. David S, Kan T, Cheng Y, Agarwal R, Jin Z, Mori Y (2009) Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer. Biochem Biophys Res Commun 378(3):605-609. doi: 10.1016/j.bbrc.2008.11.078
6. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148-1159. doi: 10.1056/NEJMra072067
7. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345(26):1890-1900. doi: 10.1056/NEJMra001375
8. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24(11):580-588. doi: 10.1016/j.tips.2003.09.011
9. Jaafari N, Hua G, Adelaide J, Jule Y, Imbert J (2008) Expression of the tachykinin receptor mRNAs in healthy human colon. Eur J Pharmacol 599(1-3):121-125. doi: 10.1016/j.ejphar.2008.09.024
10. Jeschke J, Van Neste L, Glockner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG, Ahuja N (2012) Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7(7):701-709. doi: 10.4161/epi.20445
11. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton JP, Ito T, Wang S, David S, Agarwal R, Beer DG, Abraham JM, Meltzer SJ (2007) Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 13(21):6293-6300. doi: 10.1158/1078-0432.CCR- 07-0818
12. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ (2008) Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 123(10):2331-2336. doi: 10.1002/ijc.23804
13. Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, Ueda Y, Tono T, Carey TE (2007) Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 26(39):5762-5771. doi: 10.1038/sj.onc.1210384
14. Kanazawa T, Kommareddi PK, Iwashita T, Kumar B, Misawa K, Misawa Y, Jang I, Nair TS, Iino Y, Carey TE (2009) Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res 15(7):2222-2230. doi: 10.1158/1078-0432.CCR-08-2443
15. Kanazawa T, Misawa K, Carey TE (2010) Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opin Ther Targets 14(3):289-302. doi: 10.1517/14728221003598922
16. Katz MH (2011) Multivariable analysis: a practical guide for clinicians and public health researchers. Setting up a multivariable analysis. Cambridge University Press, Cambridge
17. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C (2004) Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 279(44):45519-45527. doi: 10.1074/jbc.M408523200
18. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26(19):3128-3137. doi: 10.1200/JCO.2007.12. 7662
19. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM (2003) Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63(13):3724-3728
20. Lappano R, Maggiolini M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 10(1):47-60. doi: 10.1038/nrd3320
21. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K (1997) The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 159(10):4952-4958
22. Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, Mineta H, Carey TE (2008) Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res 14(23):7604-7613. doi: 10.1158/1078-0432.CCR-07-4673
23. Misawa K, Kanazawa T, Misawa Y, Imai A, Endo S, Hakamada K, Mineta H (2011) Hypermethylation of collagen alpha2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer. Cancer Biomarkers Sect A Disease Markers 10(3-4):135-144. doi: 10.3233/CBM-2012-0242
24. Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, Ito T, Mantzur C, Abraham JM, Meltzer SJ (2006) A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 131(3):797-808. doi: 10.1053/j.gastro.2006.06.006
25. Ovchinnikov DA, Cooper MA, Pandit P, Coman WB, Cooper-White JJ, Keith P, Wolvetang EJ, Slowey PD, Punyadeera C (2012) Tumor-suppressor gene promoter hypermethylation in Saliva of head and neck cancer patients. Transl Oncol 5(5):321-326
26. Park HL, Kim MS, Yamashita K, Westra W, Carvalho AL, Lee J, Jiang WW, Baek JH, Liu J, Osada M, Moon CS, Califano JA, Mori M, Sidransky D (2008) DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer 122(11):2498-2502. doi: 10.1002/ijc.23434
27. Park CK, Kim JE, Kim JY, Song SW, Kim JW, Choi SH, Kim TM, Lee SH, Kim IH, Park SH (2012) The changes in MGMT promoter methylation status in initial and recurrent glioblastomas. Transl Oncol 5(5):393-397
28. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA (2004) Tachykinins and tachykinin receptors: a growing family. Life Sci 74(12):1445-1463
29. Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML (2004) mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol 494(2-3):233-239. doi: 10.1016/j.ejphar.2004.05. 016
30. Rameshwar P, Gascon P (1996) Induction of negative hematopoietic regulators by neurokinin-A in bone marrow stroma. Blood 88(1):98-106
31. Rodriguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17(3):330-339. doi: 10.1038/nm.2305
32. Rosso M, Munoz M, Berger M (2012) The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. Sci World J 2012:381434. doi: 10.1100/2012/381434
33. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V (2002) The tachykinin peptide family. Pharmacol Rev 54(2):285-322
34. Van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, Wolf GT, Drumheller T, Tilley BC, Carey TE (1994) Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosom Cancer 9(3):192-206
35. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. N Engl J Med 328(3):184-194. doi: 10.1056/NEJM199301213280306
36. Xu C, Yaici ED, Conrath M, Blanchard P, Leclerc P, Benoit G, Verge D, Giuliano F (2005) Galanin and neurokinin-1 receptor immunoreactive [corrected] spinal neurons controlling the prostate and the bulbospongiosus muscle identified by transsynaptic labeling in the rat. Neuroscience 134(4):1325-1341. doi: 10.1016/j.neuroscience.2005.06.002